To the full analysis
Pacific Biosciences of California stock: growth
PACBPacific Biosciences of California reported $160.01M in revenue for fiscal 2025, up 3.9% on the prior year, up 15.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
27%
per year from 2007 to 2025, per share −8.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2007 | |
|---|---|---|---|
| Revenue | 15.2% | 5.6% | 27.0% |
| Revenue per share | 2.2% | −8.0% | −8.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $2.16M | −$21.52M | −$19.78M |
| 2008 | $901K | −$43.75M | −$44.01M |
| 2009 | $135K | −$87.7M | −$80.02M |
| 2010 | $1.67M | −$140.17M | −$127.26M |
| 2011 | $33.86M | −$109.39M | −$112.26M |
| 2012 | $25.98M | −$94.47M | −$78.53M |
| 2013 | $28.18M | −$79.29M | −$30.74M |
| 2014 | $60.59M | −$66.16M | −$53.08M |
| 2015 | $92.78M | −$31.7M | −$50.9M |
| 2016 | $90.71M | −$74.38M | −$76.14M |
| 2017 | $93.47M | −$92.19M | −$77.95M |
| 2018 | $78.63M | −$102.56M | −$68.28M |
| 2019 | $90.89M | −$84.13M | −$81.15M |
| 2020 | $78.89M | $29.4M | $18.46M |
| 2021 | $130.51M | −$181.22M | −$117.11M |
| 2022 | $128.3M | −$314.25M | −$280.14M |
| 2023 | $200.52M | −$306.74M | −$275.39M |
| 2024 | $154.01M | −$309.85M | −$212.25M |
| 2025 | $160.01M | −$546.38M | −$113.92M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.